SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma by René-Olivier Casasnovas,

Slides:

Advertisements

Similar presentations

Long-term outcome of patients in the LNH-98

Advertisements

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de.

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

Corinne Haioun Unité Hémopathies Lymphoides Hôpital Henri Mondor Créteil, France PET and Lymphoma.

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and at the End of Treatment with R-CHOP in High- Tumor Mass Follicular.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm,

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma:

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase.

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

by Timothy P. Hughes, and David M. Ross

by James O. Armitage, and Dan L. Longo

Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

The effect of variation in donor platelet function on transfusion outcome: a semirandomized controlled trial by Anne M. Kelly, Stephen F. Garner, Theodora.

How I treat elderly patients with myeloma

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.

Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose by Wolfgang Römer, Axel-R. Hanauske, Sibylle.

Nonmyeloablative conditioning for relapsed follicular lymphoma

Superior Survival after Autologous vs

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

by Alexander Röth, Andreas Hüttmann, Russell P

by Fangxin Hong, Thomas M Habermann, Leo I

Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases by Massimo Federico, Umberto Vitolo, Pier Luigi Zinzani,

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

How I treat refractory CLL

Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma Amanda J. Walker, MD, Alin Chirindel, MD, Robert.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.

Consort diagram i-scan multicentre trial NCT (clinicaltrials

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD by Gérard Socié, Noel Milpied, Ibrahim.

Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma by Marie-Hélène Delfau-Larue, Axel.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Catherine M. Pound et al. Hospital Pediatrics 2017;7:

Positron emission tomography scan in the axial plane performed in June 2007 showing intense and homogeneous increased uptake of 18-fluorodeoxyglucose within.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Nicolas Bourdel, M. D. , Maud Durand, M. D. , Pierre Gimbergues, M. D

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Positron emission tomography–computed tomography predictors of progression after DA-R-EPOCH for PMBCL by Chelsea C. Pinnix, Andrea K. Ng, Bouthaina S.

by Wendy Lim, Sara K. Vesely, and James N. George

CT (left of images) showing calcified areas and PET (right of images) scans showing increased FDG-PET metabolic activity in the mediastinal mass (A) and.

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

Initial treatment of CLL: integrating biology and functional status

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Optimizing therapy for nodal marginal zone lymphoma

Is Skull-Base to Proximal Thigh PET/CT Enough

Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia by Mohamed Bradai, Mohand Tayeb Abad, Serge Pissard, Fatima Lamraoui,

Balancing bleeding in brain metastases

Cold agglutinin disease

Presentation transcript:

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma by René-Olivier Casasnovas, Michel Meignan, Alina Berriolo-Riedinger, Stéphane Bardet, Anne Julian, Catherine Thieblemont, Pierre Vera, Serge Bologna, Josette Brière, Jean-Philippe Jais, Corinne Haioun, Bertrand Coiffier, and Franck Morschhauser Blood Volume 118(1):37-43 July 7, 2011 ©2011 by American Society of Hematology

Scheme of the treatment according to the LNH2007-3B trial. René-Olivier Casasnovas et al. Blood 2011;118:37-43 ©2011 by American Society of Hematology

PFS of 85 patients. René-Olivier Casasnovas et al. Blood 2011;118:37-43 ©2011 by American Society of Hematology

PFS of 84 patients. René-Olivier Casasnovas et al. Blood 2011;118:37-43 ©2011 by American Society of Hematology

Effect of postinduction treatment on patients' PFS. Effect of postinduction treatment on patients' PFS according to (A) PET-driven postinduction treatment and (B) PET-driven postinduction treatment and SUVmax reduction analysis. René-Olivier Casasnovas et al. Blood 2011;118:37-43 ©2011 by American Society of Hematology